10-Q: Metagenomi Reports Q1 2025 Financial Results, Provides Business Update

Sentiment:

Quarterly Report 13 May 2025 4:40 PM

Metagenomi, a precision gene editing company, announces its Q1 2025 financial results, highlighting progress in its research and development programs and collaborations.

Delay expectedEmerging data relating to MGX-001 from additional nonhuman primate studies using a bioengineered FVIII construct has demonstrated higher than expected FVIII activity, which may require additional studies and/or consideration of alternatives, potentially delaying IND submission.

Capital raiseThe company has an ATM program in place, allowing it to sell up to $75.0 million of common stock.The company filed a shelf registration on Form S-3 (the Shelf Registration Statement), which was declared effective on March 25, 2025, permitting the offering of up to $250.0 million aggregate dollar amount of shares of our common stock, preferred stock, debt securities, warrants and/or units, in one or more offerings and in any combination.

Worse than expectedCollaboration revenue decreased significantly year-over-year, indicating a slowdown in partnership-related income.

Summary

Metagenomi, Inc. reported a net loss of $25.0 million for the three months ended March 31, 2025, compared to a net loss of $25.1 million for the same period in 2024.
Collaboration revenue decreased to $4.1 million from $11.2 million year-over-year, primarily due to the termination of the Moderna agreement and decreased revenue from the Ionis agreement.
Research and development expenses were $25.1 million, down from $31.4 million in the prior year.
General and administrative expenses decreased to $6.8 million from $8.8 million.
As of March 31, 2025, the company had cash, cash equivalents, and available-for-sale marketable securities totaling $226.0 million.
The company believes its current resources will fund operations for at least the next 12 months.
Metagenomi is advancing its wholly-owned programs, including MGX-001 for hemophilia A, and collaborating with Ionis and Affini-T on other therapeutic programs.
The company plans to conduct pre-IND and ex-U.S. regulatory meetings in the second half of 2025 and submit IND and CTA submission in 2026 for MGX-001.
Affini-T exercised an option to a non-exclusive license for one of its pre-specified targets, triggering an exercise payment to the Company of $0.3 million.
The company has an ATM program in place, allowing it to sell up to $75.0 million of common stock, but no shares have been sold under this agreement as of March 31, 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is advancing its programs, the decrease in collaboration revenue and the potential delay in IND submission for MGX-001 temper the overall outlook.

Positives

The company believes its existing cash, cash equivalents and available-for-sale marketable securities will be sufficient to fund its current operating plan for at least the next 12 months.
Affini-T exercised an option to a non-exclusive license for one of its pre-specified targets, triggering an exercise payment to the Company of $0.3 million.
The company plans to conduct pre-IND and ex-U.S. regulatory meetings in the second half of 2025 and submit IND and CTA submission in 2026 for MGX-001.
General and administrative expenses decreased to $6.8 million from $8.8 million.

Negatives

Collaboration revenue decreased to $4.1 million from $11.2 million year-over-year, primarily due to the termination of the Moderna agreement and decreased revenue from the Ionis agreement.
Emerging data relating to MGX-001 from additional nonhuman primates using this bioengineered FVIII construct has, to date, demonstrated FVIII activity higher than expected, which may require additional studies and/or consider alternatives to this bioengineered FVIII construct.
The company is currently, and may in the future be, subject to securities litigation, which is expensive and could divert management attention.

Risks

The company has incurred significant losses since inception and expects to continue to incur substantial losses for the foreseeable future.
The company's operations will require substantial additional funding, and if it is unable to raise additional capital when needed, it may be forced to delay, reduce, or terminate certain programs.
The company is very early in its development efforts and has not yet initiated IND-enabling studies or clinical development of any product candidate.
The genome editing field is relatively new, and the company is subject to additional development challenges and risks due to the novel nature of its technology.
The company faces significant competition in an environment of rapid technological change.
Adverse public perception of genome editing and cellular therapy products may negatively impact demand for, or regulatory approval of, any product candidates the company may develop.
The company may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Unfavorable global economic conditions could adversely affect the company's business, financial condition, or results of operations.
The company's operations are vulnerable to interruption by disasters, terrorist activity, pandemics and other events beyond its control, which could harm its business.
The company may use artificial intelligence in its business, and challenges with properly managing its use, as well as uncertainty regarding the legal landscape surrounding the use of AI could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations.

Future Outlook

Management believes that existing cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025, of $ 226.0 million will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these unaudited condensed financial statements.

Management Comments

We are taking a stepwise approach , deploying our genome editing toolbox to develop potentially curative therapies for patients across a broad array of diseases and target organs including the liver, central nervous system, muscle, kidney, and lung, matching the right tool to each specific target.
We believe our therapeutic programs are well-positioned to leverage the clinical, regulatory, and manufacturing advancements made to date across gene therapy, gene editing, and delivery modalities to accelerate progression to clinical trials and potential approval.

Industry Context

The gene editing field is rapidly evolving, with significant competition and a strong emphasis on intellectual property. Metagenomi is positioning itself to be a leader in this space through its proprietary platform and strategic collaborations.

Comparison to Industry Standards

Metagenomi's approach to gene editing, leveraging metagenomics and AI, differentiates it from companies primarily using CRISPR/Cas9 technology, such as CRISPR Therapeutics and Editas Medicine.
The company's focus on in vivo gene editing for its wholly-owned pipeline contrasts with companies like bluebird bio, which are more focused on ex vivo cell therapy.
Metagenomi's collaboration with Ionis in the cardiometabolic space aligns with industry trends of exploring gene editing for chronic diseases, similar to Verve Therapeutics' approach.
The company's partnership with Affini-T in cell therapy mirrors the strategy of companies like Cellectis, which are developing allogeneic cell therapies using gene editing.

Legal Proceedings

A class action complaint was filed in the U.S. District Court for the Northern District of California against the company and certain of its officers and certain of its current and former directors, captioned Vreeland v. Metagenomi Inc. et al. , No. 5:24-cv-06765 (the Securities Action).
The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information concerning the Companys collaboration with Moderna in the Companys registration statement and final prospectus materials filed in January 2024 and February 2024.
The Securities Action seeks, among other things, compensatory damages as well as costs and expenses, including attorneys fees and expert fees.
The company intends to defend vigorously against this litigation.

Stakeholder Impact

Shareholders may be concerned about the decrease in collaboration revenue and the potential delay in IND submission for MGX-001.
Employees may be affected by the company's efforts to manage its growth and maintain compliance with regulatory requirements.
Customers and partners may be interested in the company's progress in developing its platform and collaborating with other companies.
Suppliers and creditors may be affected by the company's financial performance and its ability to meet its obligations.

Next Steps

Conduct pre-IND and ex-U.S. regulatory meetings in the second half of 2025.
Submit IND and CTA submission in 2026 for MGX-001.
Demonstrate NHP proof-of-concept for lead secreted protein deficiency target in 2025.
Nominate development candidate for lead secreted protein deficiency target in 2026.
Nominate one to two development candidates from the Wave 1 targets and disclose the remaining two therapeutic indications in 2025.
Initiate IND-enabling activities for the development candidates nominated in 2025, and nominate additional development candidates from the remaining Wave 1 targets in 2026.

Key Dates

Date	Description
September 2016	Metagenomi, Inc. was originally founded as Metagenomi.co, a Delaware corporation.
October 2021	The Company entered into a Strategic Collaboration and License Agreement with ModernaTX, Inc. ( Moderna) (the Moderna Agreement).
June 14, 2022	The Company entered into a Development, Option and License Agreement (the Affini-T Agreement) with Affini-T Therapeutics, Inc. (Affini-T).
November 2022	The Company entered into a Collaboration and License Agreement with Ionis Pharmaceuticals, Inc. ( Ionis) (the Ionis Agreement).
January 24, 2024	The Company completed a series of transactions, which are referred to collectively as the Reorganization.
January 26, 2024	Following the Reorganization, Metagenomi, Inc. effected a reverse stock split of the shares of common stock at a ratio of 1-for1.74692 (the Reverse Stock Split).
February 8, 2024	Metagenomi, Inc.s Form S-1 Registration Statement for its initial public offering (the IPO) was declared effective and the common stock of Metagenomi, Inc. began trading on the Nasdaq Global Select Market under the symbol MGX.
February 13, 2024	The closing date of IPO, the Company issued 6,250,000 shares of common stock at a price to the public of $ 15.00 per share.
April 26, 2024	The Company and Moderna mutually terminated the Moderna Agreement (the Termination).
July 2024	Pursuant to the terms of the Development, Option and License Agreement with Affini-T (the Affini-T Agreement), the Company received equity consideration of 933,650 shares of Affini-T common stock upon the achievement of a regulatory milestone related to the submission of drug master files to the Food and Drug Administration (FDA) in support of an investigational new drug (IND) application for Affini-Ts T-cell receptor-based therapy.
August 2024	In connection with Affini-Ts Series B extension, the Company entered into a Joinder to Series B Preferred Stock Purchase Agreement (the Series B Purchase Agreement), pursuant to which the Company purchased 33,383 shares of Series B convertible preferred stock of Affini-T (the Affini-T Series B Preferred Stock) at a purchase price of $ 9.714 per share and received warrants to purchase up to 16,691 shares of common stock at an exercise price of $ 0.01 per share, for an aggregate purchase price of approximately $ 0.3 million.
August 2024	Following our meeting with the FDA to align on key aspects of our planned IND submission, in August 2024, we nominated a lead development candidate, MGX-001.
September 26, 2024	A class action complaint was filed in the U.S. District Court for the Northern District of California against the Company and certain of the Companys officers and certain of its current and former directors, captioned Vreeland v. Metagenomi Inc. et al. , No. 5:24-cv-06765 (the Securities Action).
October 2024	We demonstrated that our novel Adenine Base Editors (ABEs) are potentially targetable to over 95% of the human genomes base pairs, a significantly wider range of sites than first-generation SpCas9 base editors.
February 10, 2025	The court appointed Mingxi Bi as lead plaintiff.
March 17, 2025	The Company filed a shelf registration on Form S-3 (the Shelf Registration Statement), which was declared effective on March 25, 2025.
March 17, 2025	The Company entered into an Open Market Sale Agreement SM (the ATM Sales Agreement) with Jefferies LLC (Jefferies).
March 25, 2025	The Shelf Registration Statement was declared effective.
March 2025	We published our latest findings in Nature Communications describing our novel, compact CAST systems, which demonstrated integration of a large, therapeutically relevant gene into the genome of human cells.
April 4, 2025	The plaintiffs filed an amended complaint.
April 14, 2025	Affini-T exercised an option to a non-exclusive license for one of its pre-specified targets, triggering an exercise payment to the Company of $ 0.3 million.
Second half of 2025	The company plans to conduct pre-IND and ex-U.S. regulatory meetings.
2026	The company plans to submit IND and CTA submission for MGX-001.

Keywords

Metagenomi, financial results, gene editing, collaboration revenue, research and development, hemophilia A, MGX-001, Ionis, Affini-T, clinical trials, regulatory approval, ATM program, marketable securities, net loss, operating expenses

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.